科兴制药2024年报：海外业务增长迅猛 全面向创新药研发转型

Core Viewpoint - The company has shown significant improvement in overall operational quality and steady growth in its main business, with a reported revenue of 1.4 billion yuan, representing a year-on-year increase of 11.75% [1] Group 1: Financial Performance - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 35.25 million yuan [1] - The overseas business revenue reached 224 million yuan, marking a year-on-year growth of approximately 61.96% [1][2] - The proportion of overseas business revenue in total revenue increased from 11% in 2023 to 16% in 2024 [2] Group 2: Research and Development - The company has transformed its R&D focus towards innovative drug development, particularly in the fields of antiviral, oncology, and autoimmune diseases, with 14 projects under research, 4 of which are in clinical stages [1] - The innovative drug GB18, targeting GDF-15 for treating cancer cachexia, has completed international patent layout and shows promising preclinical results [1] - The company is leveraging AI and computer-aided drug design (CADD) for antibody molecule design, achieving breakthroughs such as the GB12 bispecific antibody [2] Group 3: Market Expansion - The company has strategically targeted emerging markets with a population exceeding one billion and rapid economic growth, establishing subsidiaries in countries like Brazil, Mexico, Singapore, Vietnam, and Egypt [3] - Sales in emerging markets grew by over 15% year-on-year during the reporting period [3] - The company's product, EPO injection, has become a leading brand in countries such as Brazil, the Philippines, Egypt, and Peru [3]